Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3 (ALKBH3) is a Fe(II)- and 2-oxoglutarate-dependent enzyme that demethylates specific alkylated bases in single-stranded DNA and RNA, particularly 1-methyladenosine (m^1A) and 3-methylcytidine (m^3C)[2][3][4]. In DNA, ALKBH3 repairs lesions caused by alkylating agents and helps maintain genomic integrity. In RNA, especially tRNA, it modulates modifications that affect translation efficiency, ribosome assembly, and tumor cell survival. ALKBH3 is highly expressed in several cancers, promoting cell proliferation, migration, invasion, and resistance to apoptosis. Its essential roles in nucleic acid repair and RNA biology, along with its frequent overexpression in tumors, make it a compelling therapeutic target in oncology[3][4][7].
Inhibition leads to accumulation of methylated DNA/RNA bases, causing DNA damage, reduced tRNA function, impaired translation, cell cycle arrest, apoptosis, and tumor suppression[4][5].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3 (ALKBH3).